IAVA and Myriad Genetics Host Live Event to Raise Awareness about Genetic Testing and Mental Health
Clinical expert to share new research about treatment
for veterans with depression
FOR IMMEDIATE RELEASE:
November 10, 2022
New York, NY –Iraq and Afghanistan Veterans of America (IAVA) will join partner Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, for a Facebook live event on mental health and treatment options for the community on Tuesday, Nov. 15 at 1 p.m. ET.
IAVA’s Associate Director, Government Affairs, Kaitlynne Yancy, will sit down with Dr. Rachael Earls, Sr. Medical Science Liaison with Myriad Genetics, and Brian, a GeneSight-tested patient. In addition to discussing the importance of seeking mental health treatment, the panel will share information about genetic testing. The GeneSight® Psychotropic test is a genetic test that informs clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain medications commonly prescribed for depression, anxiety, ADHD and other psychiatric conditions.
“IAVA is proud to join Myriad Genetics to highlight and share critical resources available for our community,” said Yancy. “Mental health and suicide prevention have been top priorities since IAVA’s founding, and we are thrilled that there are exciting tools available that may help veterans and all Americans better address mental health challenges.”
“The GeneSight test helps clinicians by providing information that is unique to each patient about how they may metabolize or respond to certain psychiatric medications,” said Dr. Earls. “We’re grateful for the opportunity to work with IAVA to raise awareness and help more veterans get on the road to mental wellness.”
|WHO:||Kaitlynne Yancy, Associate Director, Government Affairs for IAVA|
Dr. Rachael Earls, Sr. Medical Science Liaison, Myriad Genetics
Brian, GeneSight-tested patient
|WHAT:||Mental health conditions and treatment|
|WHEN:||Tuesday, November 15th at 1:00 pm ET|
|WHERE:||Join the Facebook Live event here. The event is open to the press.|
This event will provide an overview of IAVA’s advocacy efforts for mental health legislation, as well as Myriad’s work in the mental health space. There will be time allotted for questions.
IAVA is here for our veterans and families in need. If you know a veteran or a family member of a veteran and need assistance navigating or accessing your benefits, please reach out to our Quick Reaction Force Team today, we may be able to help! Call 855-91RAPID 24/7 or visit us online at quickreactionforce.org.
The GeneSight Psychotropic test from Myriad Genetics (NASDAQ: MYGN) is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain psychiatric medications. Tens of thousands of clinicians have ordered the GeneSight test for more than 2 million patients in order to receive genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are 4 trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
IAVA is the voice for the post-9/11 veteran generation. With over 425,000 veterans and allies nationwide, IAVA is the leader in non-partisan veteran advocacy and public awareness. We drive historic impacts for veterans and IAVA’s programs are second to none. Any veteran or family member in need can reach out to IAVA’s Quick Reaction Force at quickreactionforce.org or 855-91RAPID (855-917-2743) to be connected promptly with a veteran care manager who will assist. IAVA’s The Vote Hub is a free tool to register to vote and find polling information. IAVA’s membership is always growing. Join the movement at iava.org/membership.